NAMS
NewAmsterdam Pharma Company N.V. Ordinary Shares
NASDAQ: NAMS · HEALTHCARE · BIOTECHNOLOGY
$28.43
-1.01% today
Updated 2026-04-29
Market cap
$3.27B
P/E ratio
—
P/S ratio
145.26x
EPS (TTM)
$-1.72
Dividend yield
—
52W range
$17 – $42
Volume
0.9M
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
+3.4%
Last 4 quarters
Revenue YoY growth
-99.7%
Most recent quarter
EPS YoY growth
+42.7%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+2.6%
Last 3 reports
Positive reaction rate
67%
2 of 3 quarters
Largest single-day move
+7.2%
2025-08-07
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-04 | $-0.53 | -32.7% | $30.41 | $30.14 | -0.9% |
| 2025-11-05 | $-0.61 | -51.3% | $36.53 | $37.05 | +1.4% |
| 2025-08-07 | $-0.15 | +65.9% | $23.62 | $25.31 | +7.2% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.40 | $-0.53 | -32.7% | $32000.00 | -99.7% |
| 2025-09-30 | $-0.40 | $-0.61 | -51.3% | $348000.00 | -98.8% |
| 2025-06-30 | $-0.44 | $-0.15 | +65.9% | $19.14M | +740.1% |
| 2025-03-31 | $-0.44 | $-0.30 | +31.8% | $2.98M | +112.6% |
| 2024-12-31 | $-0.96 | $-0.93 | +3.1% | $12.77M | +1490.5% |
| 2024-09-30 | $-0.45 | $-0.16 | +64.4% | $29.11M | +889.8% |
| 2024-06-30 | $-0.52 | $-0.38 | +26.9% | $2.28M | +32.7% |
| 2024-03-31 | $-0.48 | $-0.99 | -106.3% | $1.40M | — |
| 2023-12-31 | $-0.55 | $-0.54 | +1.8% | $803000.00 | — |
| 2023-09-30 | $-0.76 | $-0.56 | +25.8% | $2.94M | — |
| 2023-06-30 | $-0.42 | $-1.01 | -140.5% | $1.72M | — |
Frequently asked questions
Has NewAmsterdam Pharma Company N.V. Ordinary Shares beaten earnings estimates?
NewAmsterdam Pharma Company N.V. Ordinary Shares has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of +3.4% over the last 4 quarters.
How does NAMS stock react to earnings?
NAMS stock has moved an average of +2.6% in the trading day following earnings over its last 3 reports, with positive reactions in 67% of those quarters.
What is NewAmsterdam Pharma Company N.V. Ordinary Shares's revenue growth rate?
NewAmsterdam Pharma Company N.V. Ordinary Shares reported year-over-year revenue growth of -99.7% in its most recent quarter, with EPS growing +42.7% year-over-year.